Clinical · To Hospital
aFMT — industrialized FMT 3.0.
Our clinical brand delivers fecal microbiota transplantation to hospitals and research partners — standardized, traceable, and built on a donor-safety system and P2 + GMP manufacturing.
The technology
What is FMT 3.0
FMT 3.0 is our freeze-dried, capsule-based generation of fecal microbiota transplantation — first introduced by aFMT in 2023. Compared with earlier slurry and frozen approaches, it targets a cleaner, more standardized, room-stable product with consistent dosing — and is now the policy-recommended direction in China.
Capsule products
Optimized
FMT 3.020 capsules · 10-day course. Freeze-dried microbiome at trillion-scale CFU, with complementary strains selected by metabolomics. Multiple clinical validations.
PRO (Enhanced)
FMT 3.0 · AI-matched20 capsules · 10-day course. Optimized on real clinical-trial data with AI-assisted donor matching for personalized colonization.
Clinical products for use within qualified medical settings.
Donor safety
The SDS donor-safety system
Donors are screened against a strict, multi-stage protocol with ongoing dynamic monitoring and traceability — only a small fraction qualify.
- 18–25
- Healthy university-age donors
- 120+
- Medical screens per donor
- <2%
- Acceptance rate
Manufacturing
- P2 biosafety laboratory + GMP cleanroom
- >1,000 m² laboratory floor area
- Triple-encapsulation process for strain viability
- Cold-chain storage & controlled logistics
Collaborate with aFMT.
For hospital partnerships, clinical collaboration or FMT 3.0 supply, get in touch.